Global Information
회사소개 | 문의 | 위시리스트

세계의 수막염 백신 시장

Meningitis Vaccines Market

리서치사 Research Nester
발행일 2019년 04월 상품 코드 830896
페이지 정보 영문 312 Pages
가격
US $ 4,150 ₩ 4,971,000 PDF by E-mail (Single User License)
US $ 5,150 ₩ 6,169,000 PDF by E-mail (Corporate License)
US $ 7,150 ₩ 8,565,000 PDF by E-mail (Enterprise License)


세계의 수막염 백신 시장 Meningitis Vaccines Market
발행일 : 2019년 04월 페이지 정보 : 영문 312 Pages

세계의 수막염 백신(Meningitis Vaccines) 시장을 분석했으며, 시장의 기본 구조와 최신 상황, 주요 시장 성장 촉진요인 및 억제요인, 전체적인 시장 동향(시장 규모, 성장률) 전망(향후 10년간), 백신 종류별·구조별·최종사용자별·지역별 상세 동향, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

제1장 서론

제2장 전제조건 및 약어 리스트

제3장 분석 방법

제4장 주요 요약

제7장 시장 역학

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 동향
  • 시장 기회

제6장 리스크 분석

  • 수요 리스크
  • 공급 리스크

제7장 세계의 수막염 백신 시장 전망

  • 시장 규모와 예측
    • 시장 규모(금액 기준, 향후 10년간)
      • 연간 성장률(금액 기준, 향후 10년간)
  • 시장 점유율과 예측(금액 기준, 향후 10년간)
    • 백신별
      • 수막염균 백신(MenB, MenC, MenACWY)
      • 폐렴구균 백신(PCV, PPV)
      • Hib 백신
      • 시장 매력 분석 : 백신별
      • 시장 점유율(BPS) 분석 : 백신별
    • 구조별
      • 다당체 백신, 결합 백신 등
    • 최종사용자별
      • 병원, 클리닉, 외래수술센터(ASC) 등
    • 지역별
      • 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

제8장 북미의 수막염 백신 시장 전망

  • 거시경제 지표
  • 시장 규모와 예측(금액 기준, 통산 9년간)
  • 시장 점유율과 예측(금액 기준, 통산 9년간)
    • 백신별
    • 구조별
    • 최종사용자별
    • 국가별(미국, 캐나다)

제9장 유럽의 수막염 백신 시장 전망

  • 거시경제 지표
  • 시장 규모와 예측(금액 기준, 통산 9년간)
  • 시장 점유율과 예측(금액 기준, 통산 9년간)
    • 국가별(독일, 영국, 프랑스, 이탈리아, 스페인, 터키, 러시아 등)

제10장 아시아태평양의 수막염 백신 시장 전망

  • 거시경제 지표
  • 시장 규모와 예측(금액 기준, 통산 9년간)
  • 시장 점유율과 예측(금액 기준, 통산 9년간)
    • 국가별(인도, 중국, 일본, 한국, 호주 등)

제11장 라틴아메리카의 수막염 백신 시장 전망

  • 거시경제 지표
  • 시장 규모와 예측(금액 기준, 통산 9년간)
  • 시장 점유율과 예측(금액 기준, 통산 9년간)
    • 국가별(북아프리카 국가, 남아프리카공화국 등)

제12장 중동 및 아프리카의 수막염 백신 시장 전망

  • 거시경제 지표
  • 시장 규모와 예측(금액 기준, 통산 9년간)
  • 시장 점유율과 예측(금액 기준, 통산 9년간)
    • 국가별(미국, 캐나다)

제13장 경쟁 환경

  • 주요 기업의 시장 포지셔닝
  • 기업 개요
    • GlaxoSmithKline plc
      • 기업 개요
      • 사업 전략(성장 및 확대 전략, 유통채널 전략, 제품 전략)
      • 주요 제품
      • 재무 실적
      • 핵심성과지표(KPI)
      • 리스크 분석
      • 최근 동향
      • 각 지역에서의 존재감
      • SWOT 분석
    • Pfizer Inc.
    • Sanofi Pasteur SA
    • Merck & Co., Inc.
    • Janssen
    • Panacea
    • Hualan Biological Engineering Inc.
    • Serum Institute of India Ltd.
LSH 19.05.16

Global market of meningitis vaccine stood at USD 12,783.1 Million in 2018 and is expected to reach USD 27,522.5 Million by the end of 2027, expanding at a CAGR of 8.9% over the forecast period i.e. 2019-2027. The advancements in meningitis vaccine and growing healthcare sector globally is anticipated to further boost the demand for meningitis vaccine in future.

Geographically, North America accounted for the largest market share of 41.2% in 2018 in the revenue of meningitis vaccine market globally. The market of North America region is expected to continue its dominance over the forecast period on the back of rising demand for efficient disease preventive Vaccine across the region.

Robust research and development are going on in healthcare sector to manufacture advanced and cost-effective meningitis Vaccine. The advanced meningitis vaccine further provides precise and accurate dosing with minimalist side effects to the vaccinated population.

The adoption of advanced and high end Vaccine is rising in developing regions such as India, China, Japan and others. To gain a competitive edge, different manufacturers of medical equipment have come up with various new Vaccine to effectively aid in the prevention of meningitis.

With USD 5,999.9 Million revenue by the end of 2027 in global market, Asia-Pacific Meningitis Vaccine market is expected to showcase lucrative growth over the forecast period. This growth is primarily attributed on the back of increasing governing regulatory body initiatives in order to reduce the number of deaths caused to meningitis across the region.

With the increasing focus of people on healthcare, the Asia-Pacific meningitis vaccine market is expected to witness rapid growth throughout the forecast period. Asia-Pacific market is expected to expand at a CAGR of 9.4% over the forecast period and expected to contribute a market share of 21.8% in global meningitis vaccine market.

Additionally, favorable government initiatives to develop the healthcare infrastructure coupled with increasing healthcare expenditure across the globe is envisioned to bolster the growth of the meningitis Vaccine market robustly over the forecast period.

Moreover, Europe is estimated to grow at a CAGR of 8.7% over the forecast period contributing a market share of 25.6% in the year 2027 in the global meningitis market.

Some of the leading manufacturers in this market are Sanofi Pasteur, GSK, Pfizer, Merck and Essilor among others.

1. Introduction

  • 1.1. Market Definition
  • 1.2. Product Overview
  • 1.3. Market Segmentation
  • 1.4. Features by Popular Products Available

2. Assumptions and Acronyms

3. Research Methodology

4. Executive Summary- Global Meningitis Vaccine Market

5. Market Dynamics

  • 5.1. Drivers
  • 5.2. Restraints
  • 5.3. Trends
  • 5.4. Opportunities

6. Risk Analysis

  • 6.1. Demand Risk
  • 6.2. Supply Risk

7. Global Meningitis Vaccine Market Outlook

  • 7.1. Market Size and Forecast, 2018-2027
    • 7.1.1. By Value (USD Million)
      • 7.1.1.1. Y-o-Y Growth (%), 2019-2027
  • 7.2. Market Share and Forecast, 2018-2027
    • 7.2.1. By Vaccine
      • 7.2.1.1. Meningitis Vaccine Market Share (%), By Vaccine (2018, 2027F)
        • 7.2.1.1.1. Meningococcal Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 7.2.1.1.1.1. MenB, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 7.2.1.1.1.2. MenC, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 7.2.1.1.1.3. MenACWY, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 7.2.1.1.2. Pneumococcal vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 7.2.1.1.2.1. PCV, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 7.2.1.1.2.2. PPV, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 7.2.1.1.3. Hib, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 7.2.1.2. Market Attractiveness Analysis, By Vaccine
      • 7.2.1.3. Market Contribution and BPS Analysis, 2018 & 2027, By Vaccine
    • 7.2.2. By Composition
      • 7.2.2.1. Meningitis Vaccine Market Share (%), By Composition (2018, 2027F)
        • 7.2.2.1.1. Polysaccharide Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 7.2.2.1.2. Conjugate Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 7.2.2.1.3. Others, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 7.2.2.2. Market Attractiveness Analysis, By Composition
      • 7.2.2.3. Market Contribution and BPS Analysis, 2018 & 2027, By Composition
    • 7.2.3. By End User
      • 7.2.3.1. Meningitis Vaccine Market Share (%), By End User (2018, 2027F)
        • 7.2.3.1.1. Hospitals, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 7.2.3.1.2. Clinics, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 7.2.3.1.3. Ambulatory Surgical centers, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 7.2.3.1.4. Others, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 7.2.3.2. Market Attractiveness Analysis, By End User
      • 7.2.3.3. Market Contribution and BPS Analysis, 2018 & 2027, By End User
    • 7.2.4. By Region
      • 7.2.4.1. Meningitis Vaccine Market Share (%), By Region (2018,2027F)
        • 7.2.4.1.1. North America
        • 7.2.4.1.2. Europe
        • 7.2.4.1.3. Asia Pacific
        • 7.2.4.1.4. Latin America
        • 7.2.4.1.5. Middle East and Africa

8. North America Meningitis Vaccine Market Outlook

8.1. Macro-Economic Indicators impacting the North America Meningitis Vaccine Market

  • 8.2. Market Size and Forecast, 2018-2027
    • 8.2.1. By Value (USD Million)
      • 8.2.1.1. Y-o-Y Growth (%), 2019-2027

8.3. Market Share and Forecast, 2018-2027

    • 8.3.1. By Vaccine
      • 8.3.1.1. Meningitis Vaccine Market Share (%), By Vaccine (2018, 2027F)
        • 8.3.1.1.1. Meningococcal Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 8.3.1.1.1.1. MenB, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 8.3.1.1.1.2. MenC, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 8.3.1.1.1.3. MenACWY, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 8.3.1.1.2. Pneumococcal vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 8.3.1.1.2.1. PCV, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 8.3.1.1.2.2. PPV, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 8.3.1.1.3. Hib, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 8.3.1.2. Market Attractiveness Analysis, By Vaccine
      • 8.3.1.3. Market Contribution and BPS Analysis, 2018 & 2027, By Vaccine
    • 8.3.2. By Composition
      • 8.3.2.1. Meningitis Vaccine Market Share (%), By Composition (2018, 2027F)
        • 8.3.2.1.1. Polysaccharide Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 8.3.2.1.2. Conjugate Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 8.3.2.1.3. Others, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 8.3.2.2. Market Attractiveness Analysis, By Composition
      • 8.3.2.3. Market Contribution and BPS Analysis, 2018 & 2027, By Composition
    • 8.3.3. By End User
      • 8.3.3.1. Meningitis Vaccine Market Share (%), By End User (2018, 2027F)
        • 8.3.3.1.1. Hospitals, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 8.3.3.1.2. Clinics, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 8.3.3.1.3. Ambulatory Surgical centers, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 8.3.3.1.4. Others, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 8.3.3.2. Market Attractiveness Analysis, By End User
      • 8.3.3.3. Market Contribution and BPS Analysis, 2018 & 2027, By End User
    • 8.3.4. By Country
      • 8.3.4.1. Meningitis Vaccine Market Share (%), By Country (2018,2027F)
        • 8.3.4.1.1. United States & Canada, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027

9. Europe Meningitis Vaccine Market Outlook

  • 9.1. Macro-Economic Indicators impacting the Europe Meningitis Vaccine Market
  • 9.2. Market Size and Forecast, 2018-2027
    • 9.2.1. By Value (USD Million)
      • 9.2.1.1. Y-o-Y Growth (%), 2019-2027

9.3. Market Share and Forecast, 2018-2027

    • 9.3.1. By Vaccine
      • 9.3.1.1. Meningitis Vaccine Market Share (%), By Vaccine (2018, 2027F)
        • 9.3.1.1.1. Meningococcal Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.1.1.1.1. MenB, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.1.1.1.2. MenC, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.1.1.1.3. MenACWY, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.1.1.2. Pneumococcal vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.1.1.2.1. PCV, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.1.1.2.2. PPV, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.1.1.3. Hib, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 9.3.1.2. Market Attractiveness Analysis, By Vaccine
      • 9.3.1.3. Market Contribution and BPS Analysis, 2018 & 2027, By Vaccine
    • 9.3.2. By Composition
      • 9.3.2.1. Meningitis Vaccine Market Share (%), By Composition (2018, 2027F)
        • 9.3.2.1.1. Polysaccharide Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.2.1.2. Conjugate Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.2.1.3. Others, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 9.3.2.2. Market Attractiveness Analysis, By Composition
      • 9.3.2.3. Market Contribution and BPS Analysis, 2018 & 2027, By Composition
    • 9.3.3. By End User
      • 9.3.3.1. Meningitis Vaccine Market Share (%), By End User (2018, 2027F)
        • 9.3.3.1.1. Hospitals, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.3.1.2. Clinics, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.3.1.3. Ambulatory Surgical centers, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.3.1.4. Others, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 9.3.3.2. Market Attractiveness Analysis, By End User
      • 9.3.3.3. Market Contribution and BPS Analysis, 2018 & 2027, By End User
    • 9.3.4. By Country
      • 9.3.4.1. Meningitis Vaccine Market Share (%), By Country (2018,2027F)
        • 9.3.4.1.1. Germany, United Kingdom & France, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.4.1.2. Italy, Spain & Turkey, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 9.3.4.1.3. Russia & rest of Europe, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027

10. Asia Pacific Meningitis Vaccine Market Outlook

  • 10.1. Macro-Economic Indicators impacting the Asia Pacific Meningitis Vaccine Market
  • 10.2. Market Size and Forecast, 2018-2027
    • 10.2.1. By Value (USD Million)
      • 10.2.1.1. Y-o-Y Growth (%), 2019-2027

10.3. Market Share and Forecast, 2018-2027

    • 10.3.1. By Vaccine
      • 10.3.1.1. Meningitis Vaccine Market Share (%), By Vaccine (2018, 2027F)
        • 10.3.1.1.1. Meningococcal Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 10.3.1.1.1.1. MenB, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 10.3.1.1.1.2. MenC, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 10.3.1.1.1.3. MenACWY, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 10.3.1.1.2. Pneumococcal vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 10.3.1.1.2.1. PCV, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 10.3.1.1.2.2. PPV, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 10.3.1.1.3. Hib, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 10.3.1.2. Market Attractiveness Analysis, By Vaccine
      • 10.3.1.3. Market Contribution and BPS Analysis, 2018 & 2027, By Vaccine
    • 10.3.2. By Composition
      • 10.3.2.1. Meningitis Vaccine Market Share (%), By Composition (2018, 2027F)
        • 10.3.2.1.1. Polysaccharide Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 10.3.2.1.2. Conjugate Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 10.3.2.1.3. Others, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 10.3.2.2. Market Attractiveness Analysis, By Composition
      • 10.3.2.3. Market Contribution and BPS Analysis, 2018 & 2027, By Composition
    • 10.3.3. By End User
      • 10.3.3.1. Meningitis Vaccine Market Share (%), By End User (2018, 2027F)
        • 10.3.3.1.1. Hospitals, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 10.3.3.1.2. Clinics, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 10.3.3.1.3. Ambulatory Surgical centers, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 10.3.3.1.4. Others, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 10.3.3.2. Market Attractiveness Analysis, By End User
      • 10.3.3.3. Market Contribution and BPS Analysis, 2018 & 2027, By End User
    • 10.3.4. By Country
      • 10.3.4.1. Meningitis Vaccine Market Share (%), By Country (2018,2027F)
        • 10.3.4.1.1. India, China and Japan, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 10.3.4.1.2. South Korea, Australia & Rest of Asia Pacific 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027

11. Latin America Meningitis Vaccine Market Outlook

  • 11.1. Macro-Economic Indicators impacting the Latin America Meningitis Vaccine Market
  • 11.2. Market Size and Forecast, 2018-2027
    • 11.2.1. By Value (USD Million)
      • 11.2.1.1. Y-o-Y Growth (%), 2019-2027

11.3. Market Share and Forecast, 2018-2027

    • 11.3.1. By Vaccine
      • 11.3.1.1. Meningitis Vaccine Market Share (%), By Vaccine (2018, 2027F)
        • 11.3.1.1.1. Meningococcal Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 11.3.1.1.1.1. MenB, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 11.3.1.1.1.2. MenC, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 11.3.1.1.1.3. MenACWY, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 11.3.1.1.2. Pneumococcal vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 11.3.1.1.2.1. PCV, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 11.3.1.1.2.2. PPV, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 11.3.1.1.3. Hib, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 11.3.1.2. Market Attractiveness Analysis, By Vaccine
      • 11.3.1.3. Market Contribution and BPS Analysis, 2018 & 2027, By Vaccine
    • 11.3.2. By Composition
      • 11.3.2.1. Meningitis Vaccine Market Share (%), By Composition (2018, 2027F)
        • 11.3.2.1.1. Polysaccharide Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 11.3.2.1.2. Conjugate Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 11.3.2.1.3. Others, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 11.3.2.2. Market Attractiveness Analysis, By Composition
      • 11.3.2.3. Market Contribution and BPS Analysis, 2018 & 2027, By Composition
    • 11.3.3. By End User
      • 11.3.3.1. Meningitis Vaccine Market Share (%), By End User (2018, 2027F)
        • 11.3.3.1.1. Hospitals, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 11.3.3.1.2. Clinics, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 11.3.3.1.3. Ambulatory Surgical centers, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 11.3.3.1.4. Others, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 11.3.3.2. Market Attractiveness Analysis, By End User
      • 11.3.3.3. Market Contribution and BPS Analysis, 2018 & 2027, By End User
    • 11.3.4. By Country
      • 11.3.4.1. Meningitis Vaccine Market Share (%), By Country (2018,2027F)
        • 11.3.4.1.1. Brazil, Mexico & Rest of Latin America, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027

12. Middle East and Africa Meningitis Vaccine Market Outlook

  • 12.1. Macro-Economic Indicators impacting the Middle East and Africa Meningitis Vaccine Market
  • 12.2. Market Size and Forecast, 2018-2027
    • 12.2.1. By Value (USD Million)
      • 12.2.1.1. Y-o-Y Growth (%), 2019-2027

12.3. Market Share and Forecast, 2018-2027

    • 12.3.1. By Vaccine
      • 12.3.1.1. Meningitis Vaccine Market Share (%), By Vaccine (2018, 2027F)
        • 12.3.1.1.1. Meningococcal Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 12.3.1.1.1.1. MenB, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 12.3.1.1.1.2. MenC, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 12.3.1.1.1.3. MenACWY, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 12.3.1.1.2. Pneumococcal vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 12.3.1.1.2.1. PCV, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 12.3.1.1.2.2. PPV, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 12.3.1.1.3. Hib, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 12.3.1.2. Market Attractiveness Analysis, By Vaccine
      • 12.3.1.3. Market Contribution and BPS Analysis, 2018 & 2027, By Vaccine
    • 12.3.2. By Composition
      • 12.3.2.1. Meningitis Vaccine Market Share (%), By Composition (2018, 2027F)
        • 12.3.2.1.1. Polysaccharide Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 12.3.2.1.2. Conjugate Vaccine, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 12.3.2.1.3. Others, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 12.3.2.2. Market Attractiveness Analysis, By Composition
      • 12.3.2.3. Market Contribution and BPS Analysis, 2018 & 2027, By Composition
    • 12.3.3. By End User
      • 12.3.3.1. Meningitis Vaccine Market Share (%), By End User (2018, 2027F)
        • 12.3.3.1.1. Hospitals, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 12.3.3.1.2. Clinics, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 12.3.3.1.3. Ambulatory Surgical centers, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 12.3.3.1.4. Others, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
      • 12.3.3.2. Market Attractiveness Analysis, By End User
      • 12.3.3.3. Market Contribution and BPS Analysis, 2018 & 2027, By End User
    • 12.3.4. By Country
      • 12.3.4.1. Meningitis Vaccine Market Share (%), By Country (2018,2027F)
        • 12.3.4.1.1. Middle East & Africa, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027
        • 12.3.4.1.1.1. North Africa, South Africa & Rest of Africa, 2018-2027F (USD Million) & Y-o-Y Growth (%), 2019-2027

13. Competitive Landscape

  • 13.1. Competitive Positioning of Major Players in Global Meningitis Vaccine Market
  • 13.2. Company Profiles
    • 13.2.1. GlaxoSmithKline plc
      • 13.2.1.1. Company Overview
      • 13.2.1.2. Business Strategy
        • 13.2.1.2.1. Growth Expansion Strategy
        • 13.2.1.2.2. Distribution Channel Strategy
        • 13.2.1.2.3. Product Strategy
      • 13.2.1.3. Key Product Offerings
      • 13.2.1.4. Financial Performance
      • 13.2.1.5. Key Performance Indicators
      • 13.2.1.6. Risk Analysis
      • 13.2.1.7. Recent Development
      • 13.2.1.8. Regional Presence
      • 13.2.1.9. SWOT Analysis
    • 13.2.2. Pfizer Inc.
    • 13.2.3. Sanofi Pasteur SA
    • 13.2.4. Merck & Co., Inc.
    • 13.2.5. Janssen
    • 13.2.6. Panacea
    • 13.2.7. Hualan Biological Engineering Inc.
    • 13.2.8. Serum Institute of India Ltd.
Back to Top
전화 문의
F A Q